Global Kidney Cancer Drugs Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Kidney Cancer Drugs Market
2.2 Comparative Analysis: Global Kidney Cancer Drugs Market, By Geography, 2018 and 2026 (Value %)

Chapter 3 Global Kidney Cancer Drugs Market Overview
3.1 Market Dynamics and Overview
3.2 Market Drivers
3.2.1 Rising Incidence of Kidney Cancer Expected to Boost Market Growth
3.2.2 Increasing Geriatric Population Likely to Fuel the Growth of Kidney Cancer Drugs Market
3.2.2.1.1 Global Percentage Change in the World’s Population by Age: 2010-2050
3.2.3 Approval of Novel Molecules is Expected to Drive Market Growth
3.3 Market Restraints
3.3.1 High Prices of Branded Cancer Drugs might Impede the Growth of the Market
3.3.2 Increasing Preference for Generic Drug Variants might Negatively Influence the Market Growth
3.4 Market Opportunities
3.4.1 Focusing on Emerging Markets
3.5 Event Impact Analysis
3.6 Regulatory Framework
3.7 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography
3.8 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2018 (Value %)

Chapter 4 Global Kidney Cancer Drugs Market, by Major Branded Drugs
4.1 Overview
4.1.1 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2016 – 2026 (USD Million)
4.2 Sutent (Sunitinib)
4.2.1 Global Sutent (Sunitinib) Market Revenue, 2016 – 2026 (USD Million)
4.3 Nexavar (Sorafenib)
4.3.1 Global Nexavar (Sorafenib) Market Revenue, 2016 – 2026 (USD Million)
4.4 Afinitor (Everolimus)
4.4.1 Global Afinitor (Everolimus) Market Revenue, 2016 – 2026 (USD Million)
4.5 Votrient (Pazopanib)
4.5.1 Global Votrient (Pazopanib) Market Revenue, 2016 – 2026 (USD Million)
4.6 Inlyta (Axitinib)
4.6.1 Global Inlyta (Axitinib) Market Revenue, 2016 – 2026 (USD Million)
4.7 Avastin (Bevacizumab)
4.7.1 Global Avastin (Bevacizumab) Market Revenue, 2016 – 2026 (USD Million)
4.8 Torisel (Temsirolimus)
4.8.1 Global Torisel (Temsirolimus) Market Revenue, 2016 – 2026 (USD Million)
4.9 Proleukin (Aldesleukin)
4.9.1 Global Proleukin (Aldesleukin) Market Revenue, 2016 – 2026 (USD Million)

Chapter 5 Global Kidney Cancer Drugs Market, Pipeline Analysis
5.1 Overview
5.1.1 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 – 2026 (USD Million)
5.2 Opdivo (Nivolumab) (Bristol-Myers Squibb)
5.2.1 Global Opdivo Market Revenue, 2015 – 2026 (USD Million)
5.3 Keytruda (Anti PD 1) (Pembrolizumab) (Merck & Co., Inc.)
5.3.1 Global Keytruda Market Revenue, 2015 – 2026 (USD Million)
5.4 Cabozantinib (XL184) (Exelixis, Inc.)
5.4.1 Global Cabozantinib Market Revenue, 2017 – 2026 (USD Million)
5.5 AGS-003 (Argus Therapeutics, Inc.)
5.5.1 Global AGS-003 Market Revenue, 2017 – 2026 (USD Million)
5.6 Dovitinib (TK1258) [Novartis AG]
5.6.1 Global Dovitinib Market Revenue, 2018 – 2026 (USD Million)

Chapter 6 Global Kidney Cancer Drugs Market, by Geography
6.1 Overview
6.1.1 Global Kidney Cancer Drugs Market Revenue, by Geography, 2016 – 2026 (USD Million)
6.2 North America
6.2.1 North America Kidney Cancer Drugs Market Revenue, 2016–2026 (USD Million)
6.3 Europe
6.3.1 Europe Kidney Cancer Drugs Market Revenue, 2016 - 2026 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Kidney Cancer Drugs Market Revenue, 2016 - 2026 (USD Million)
6.5 Rest of the World (RoW)
6.5.1 Rest of the World Kidney Cancer Drugs Market Revenue, 2016 - 2026 (USD Million)

Chapter 7 Recommendations

Chapter 8 Company Profiles
8.1 Bayer AG
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategy
8.1.5 Recent Developments
8.2 F. Hoffmann-La Roche, Ltd.
8.2.1 Company Overview
8.2.2 Financial Overview
8.2.3 Product Portfolio
8.2.4 Business Strategy
8.2.5 Recent Developments
8.3 GlaxoSmithKline, plc
8.3.1 Company Overview
8.3.2 Financial Overview
8.3.3 Product Portfolio
8.3.4 Business Strategy
8.3.5 Recent Developments
8.4 Novartis AG
8.4.1 Company Overview
8.4.2 Financial Overview
8.4.3 Product Portfolio
8.4.4 Business Strategy
8.4.5 Recent Developments
8.5 Pfizer, Inc.
8.5.1 Company Overview
8.5.2 Financial Overview
8.5.3 Product Portfolio
8.5.4 Business Strategy
8.5.5 Recent Developments